New feature: Customize your PLUS research experience with
My Preferences
.
Learn more
.
Skip to main content
Create Account
Training Center
Contact Us
Questions? Comments?
Contact us.
Email:
PLUS@pli.edu
Phone:
877.900.5291
PLI.edu
SIGN IN
Search
Browse
All Content
Books
- Answer Books
- Course Handbooks
- Journals
- Insights
- Treatises
Forms & Checklists
Transcripts
My Bookshelf
My History
< Back To Results
1 in 1 results
Previous Result
Next Result
Trial by Jury 2013
Chair(s):
David R. Marriott
Practice Area:
Arguments (Litigation),
Closing arguments,
Cross-examination,
Direct examination,
Jury trials,
Litigation,
Trial,
Witnesses
Published:
Nov 2013
i
Other versions can be found in the
Related Items
tab.
ISBN:
9781402421150
PLI Item #:
43147
CHB Spine #:
H931, H932
This version is not current.
Click here for the most recent version.
Search
Email
Print
Add To Bookshelf
Permalink
Table of Contents
Related Items
Select All
Front Matter
Faculty Bios
Table of Contents to Vol. 1
Table of Contents to Vol. 2
Chapter 1. Ensuring an Impartial Jury in the Age of Social Media
Chapter 2. Effective Defense Voir Dire: Making Sense of Jurors’ Experiences
Chapter 3. Let’s Talk: Addressing the Challenges of Internet-Era Jurors
Chapter 4. Scientific Jury Selection: History, Practice, And Controversy
Chapter 5. Jury Questionnaire, United States District Court, Southern District of New York
Chapter 6. Friend or Foe? Social Media, the Jury, and You
Chapter 7. Jury Selection—Model Voir Dire Questions Promulgated by Directive #21-06—Revised Procedures and Questions
Chapter 8. In Re: Visa Check/Mastermoney Antitrust Litigation, Jury Questionnaire
Chapter 9. Huntsman Corporation v. Credit Suisse Securities (USA), L.L.C., et al., Jury Questionnaire
Chapter 10. Novartis Pharmaceuticals Corporation, Novartis Pharma AG, and Novartis International Pharmaceutical Ltd. v. Teva Pharmaceuticals USA, Inc., the Parties’ Proposed Voir Dire
Chapter 11. Persuasion in Opening Statement, Generating Interest in a Convincing Manner
Chapter 12. Succeeding in the Opening Statement
Chapter 13. Storytelling in Legal Arguments
Chapter 14. Liberty Media Corp. et al. v. Vivendi Universal S.A., et al., Opening Statement by R. Stan Mortenson
Chapter 15. Liberty Media Corp. et al. v. Vivendi Universal S.A., et al., Opening Statement by Jim Quinn
Chapter 16. Novartis Pharmaceuticals Corporation, Novartis Pharma AG, and Novartis International Pharmaceutical Ltd. v. Teva Pharmaceuticals USA, Inc., Opening Statement by Evan R. Chesler
Chapter 17. Direct Examination: Making the Facts Understandable
Chapter 18. An In-Depth Look at Direct Examination of Expert Witnesses
Chapter 19. Direct Examination, a Forgotten Art
Chapter 20. Apple Inc. v. Samsung Electronics Co., Ltd., et al., Direct Examination
Chapter 21. Apple Inc. v. Samsung Electronics Co., Ltd., et al., Direct Examination
Chapter 22. Novartis Pharmaceuticals Corporation, Novartis Pharma AG, And Novartis International Pharmaceutical Ltd. v. Teva Pharmaceuticals USA, Inc., Direct Examination
Chapter 23. Ethical Pitfalls in Jury Trials
Chapter 24. Armchair Jury Consultants: The Legal Implications and Benefits of Online Research of Prospective Jurors in the Facebook Era
Chapter 25. Internet Investigations of Jurors: Ethical and Strategic Considerations
Chapter 26. Cross-Examination at Trial: Strategies for the Deposition
Chapter 27. Pennsylvania Legal Aid Network Cross-Examination of a Lay Witness
Chapter 28. Trial Strategy, Prior Statements
Chapter 29. Novartis Pharmaceuticals Corporation, Novartis Pharma AG, and Novartis International Pharmaceutical Ltd. v. Teva Pharmaceuticals USA, Inc., Cross-Examination by David R. Marriott
Chapter 30. In Re: Vivendi Universal, S.A. Securities Litigation, Cross-Examination by Daniel Slifkin
Chapter 31. Apple Inc. v. Samsung Electronics Co., Ltd., et al., Cross-Examination by William F. Lee
Chapter 32. Closing Argument: Through the Eyes of a Trial Advocate
Chapter 33. Closing Argument from the Defense Perspective
Chapter 34. Crafting a Successful Closing Argument
Chapter 35. In Re: Vivendi Universal, S.A. Securities Litigation, Vivendi’s Closing Argument with Demonstratives
Chapter 36. Novartis Pharmaceuticals Corporation, Novartis Pharma AG, and Novartis International Pharmaceutical Ltd. v. Teva Pharmaceuticals USA, Inc., Plaintiff’s Closing Argument by Evan R. Chesler
Index
About Us